 Adam Terella
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 5 | 2021 | 756 | 1.330 |
Why?
| | Facial Neoplasms | 2 | 2019 | 17 | 1.290 |
Why?
| | Mohs Surgery | 4 | 2021 | 24 | 1.160 |
Why?
| | Forehead | 3 | 2019 | 5 | 1.010 |
Why?
| | Tissue Expansion | 2 | 2021 | 11 | 0.860 |
Why?
| | Dermatofibrosarcoma | 2 | 2019 | 9 | 0.810 |
Why?
| | Skull Base Neoplasms | 1 | 2022 | 24 | 0.790 |
Why?
| | Postoperative Complications | 5 | 2022 | 2128 | 0.700 |
Why?
| | Surgical Flaps | 3 | 2021 | 121 | 0.660 |
Why?
| | Cheek | 1 | 2019 | 16 | 0.640 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2019 | 19 | 0.640 |
Why?
| | Endoscopy | 3 | 2022 | 246 | 0.630 |
Why?
| | Skin | 1 | 2021 | 655 | 0.560 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 858 | 0.480 |
Why?
| | Blepharoplasty | 1 | 2013 | 5 | 0.430 |
Why?
| | Eyelids | 1 | 2013 | 29 | 0.420 |
Why?
| | Eyebrows | 1 | 2012 | 2 | 0.420 |
Why?
| | Rhytidoplasty | 1 | 2012 | 5 | 0.410 |
Why?
| | Orbit | 1 | 2013 | 59 | 0.410 |
Why?
| | Bone Morphogenetic Protein 2 | 1 | 2010 | 75 | 0.340 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 89 | 0.330 |
Why?
| | Skull | 1 | 2010 | 119 | 0.320 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 561 | 0.310 |
Why?
| | Osteogenesis | 1 | 2010 | 183 | 0.300 |
Why?
| | Biopolymers | 1 | 2022 | 26 | 0.200 |
Why?
| | Skull Base | 1 | 2022 | 39 | 0.200 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 28 | 0.200 |
Why?
| | Chinchilla | 1 | 2022 | 37 | 0.200 |
Why?
| | Surgical Wound | 1 | 2021 | 18 | 0.190 |
Why?
| | Scalp | 1 | 2021 | 29 | 0.190 |
Why?
| | Perfusion | 1 | 2021 | 148 | 0.180 |
Why?
| | Carcinoma, Basal Cell | 1 | 2021 | 68 | 0.170 |
Why?
| | Sulfhydryl Compounds | 1 | 2022 | 177 | 0.170 |
Why?
| | Wound Healing | 1 | 2020 | 258 | 0.150 |
Why?
| | Humans | 17 | 2022 | 114662 | 0.150 |
Why?
| | Accessory Nerve Injuries | 1 | 2017 | 2 | 0.150 |
Why?
| | Cranial Fossa, Anterior | 1 | 2017 | 2 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 427 | 0.140 |
Why?
| | Interferon-alpha | 3 | 2009 | 186 | 0.140 |
Why?
| | Arm | 1 | 2017 | 104 | 0.140 |
Why?
| | Bone Transplantation | 1 | 2017 | 98 | 0.130 |
Why?
| | Antiviral Agents | 3 | 2009 | 645 | 0.130 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2017 | 154 | 0.130 |
Why?
| | Hepatitis C | 2 | 2009 | 219 | 0.110 |
Why?
| | Liver Transplantation | 3 | 2004 | 707 | 0.100 |
Why?
| | Hematoma | 1 | 2013 | 49 | 0.100 |
Why?
| | Dry Eye Syndromes | 1 | 2013 | 28 | 0.100 |
Why?
| | Skin Aging | 1 | 2012 | 19 | 0.100 |
Why?
| | Rejuvenation | 1 | 2012 | 14 | 0.100 |
Why?
| | Corneal Injuries | 1 | 2013 | 33 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2013 | 74 | 0.100 |
Why?
| | Ribavirin | 2 | 2003 | 89 | 0.100 |
Why?
| | Vision Disorders | 1 | 2013 | 130 | 0.100 |
Why?
| | Hepatitis C, Chronic | 2 | 2004 | 151 | 0.100 |
Why?
| | Norbornanes | 1 | 2010 | 13 | 0.090 |
Why?
| | Anhydrides | 1 | 2010 | 18 | 0.090 |
Why?
| | X-Ray Microtomography | 1 | 2010 | 73 | 0.090 |
Why?
| | Histiocytoma | 1 | 2009 | 2 | 0.090 |
Why?
| | Neurothekeoma | 1 | 2009 | 4 | 0.090 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2009 | 6 | 0.080 |
Why?
| | Photochemistry | 1 | 2010 | 125 | 0.080 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 21 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2022 | 12546 | 0.080 |
Why?
| | Soft Tissue Neoplasms | 1 | 2009 | 90 | 0.080 |
Why?
| | Hepacivirus | 3 | 2009 | 229 | 0.070 |
Why?
| | Tissue Scaffolds | 1 | 2010 | 179 | 0.070 |
Why?
| | Middle Aged | 6 | 2021 | 26733 | 0.070 |
Why?
| | RNA, Viral | 3 | 2009 | 565 | 0.070 |
Why?
| | Animals | 2 | 2022 | 31699 | 0.070 |
Why?
| | Male | 7 | 2021 | 55583 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2218 | 0.060 |
Why?
| | Health Personnel | 1 | 2009 | 574 | 0.060 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 211 | 0.050 |
Why?
| | Rats | 1 | 2010 | 4958 | 0.050 |
Why?
| | Retreatment | 1 | 2021 | 67 | 0.050 |
Why?
| | Preoperative Period | 1 | 2021 | 103 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2004 | 506 | 0.040 |
Why?
| | Virus Replication | 1 | 2002 | 395 | 0.040 |
Why?
| | Graft Rejection | 1 | 2003 | 513 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2003 | 541 | 0.040 |
Why?
| | Bone Regeneration | 1 | 2017 | 21 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2004 | 1072 | 0.030 |
Why?
| | Electromyography | 1 | 2017 | 326 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2009 | 1230 | 0.030 |
Why?
| | Mutation | 1 | 2002 | 3345 | 0.020 |
Why?
| | Cohort Studies | 2 | 2017 | 4895 | 0.020 |
Why?
| | Viral Load | 2 | 2004 | 405 | 0.020 |
Why?
| | Female | 7 | 2017 | 59493 | 0.020 |
Why?
| | Treatment Outcome | 3 | 2009 | 9088 | 0.020 |
Why?
| | Needlestick Injuries | 1 | 2009 | 4 | 0.020 |
Why?
| | Blood-Borne Pathogens | 1 | 2009 | 6 | 0.020 |
Why?
| | Adult | 5 | 2017 | 30544 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4411 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2285 | 0.020 |
Why?
| | Occupational Exposure | 1 | 2009 | 255 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1342 | 0.020 |
Why?
| | Pilot Projects | 1 | 2009 | 1373 | 0.020 |
Why?
| | Prednisolone | 1 | 2003 | 75 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 2003 | 86 | 0.010 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2002 | 80 | 0.010 |
Why?
| | HIV | 1 | 2003 | 208 | 0.010 |
Why?
| | Aged | 3 | 2004 | 19069 | 0.010 |
Why?
| | Survival Analysis | 1 | 2004 | 1211 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1167 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 641 | 0.010 |
Why?
| | Acute Disease | 1 | 2003 | 911 | 0.010 |
Why?
| | Recurrence | 1 | 2003 | 935 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2004 | 1430 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 646 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2003 | 532 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2114 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 1982 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2004 | 726 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4622 | 0.010 |
Why?
| | Genetic Variation | 1 | 2002 | 870 | 0.010 |
Why?
| | Cell Line | 1 | 2002 | 2636 | 0.010 |
Why?
| | Infant | 1 | 2009 | 7961 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 9114 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2004 | 4408 | 0.010 |
Why?
| | Child | 1 | 2009 | 18412 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2004 | 2094 | 0.010 |
Why?
| | Adolescent | 1 | 2004 | 17841 | 0.000 |
Why?
|
|
Terella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|